7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
#Candidiasis #candida ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Bartonella Infections in HIV-AIDS
Preferred Therapy
For Bacillary Angiomatosis, Peliosis Hepatis, Bacteremia, and Osteomyelitis:
for Treating Bartonella ... Infections in HIV-AIDS ... #Prevention #Treatment ... #management #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
and Treating HHV ... those with KS-IRIS ... #Prevention #Treatment ... #management #opportunistic ... #pharmacology
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
osteomyelitis, cutaneous abscesses ... Parvovirus B19 • Candida ... Herpes simplex • Bartonella ... infection Treatment ... #Diagnosis #Management
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
for Preventing ... with ARV (see Table ... #Prevention #Treatment ... #management #opportunistic ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Please refer to the table ... #Prevention #Treatment ... #management #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Avium Complex in HIV-AIDS ... please refer to Table ... #Prevention #Treatment ... #management #opportunistic ... #pharmacology